Arcus Biosciences, Inc.

RCUSNYSE • USD
16.54 USD
↘ 0.32 (1.92%)🟢LIVE (AS OF 01:40 PM EST)
🟢Market: OPEN

RCUS is currently priced at $16.54. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 16, 2026.

Open?$16.84
High?$17.11
Low?$12.59
Prev. Close?$16.86
Volume?432.4K
Avg. Volume?2.2M
VWAP?$16.61
Rel. Volume?0.20x
Bid / Ask
Bid?$16.56 × 300
Ask?$16.60 × 200
Spread?$0.04
Midpoint?$16.58
Valuation & Ratios
Market Cap?2.4B
Shares Out?144.0M
Float?90.6M
Float %?71.1%
P/E Ratio?N/A
P/B Ratio?6.78
EPS?-$3.15
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Employees
601
Market Cap
2.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2018-03-15
Address
3928 POINT EDEN WAY
HAYWARD, CA 94545
Phone: (510) 694-6200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
1
Momentum?
50
Short Sent.?
35
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.08Distress
Confidence?67%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.55%High
Short Interest?13.2M
Days to Cover?3.6
Free Float90.6M
Avg Daily Volume3.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?3.34Strong
Quick Ratio?3.34Strong
Cash Ratio?0.76Adequate
Debt/Equity?0.28Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
27
6.78FAIR▾
P/S?
Peers
100
S&P
3
24.28HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
23.79HIGH▾
Returns & Efficiency
ROE?
S&P
3
-126.5%WEAK▾
ROA?
S&P
3
-55.4%WEAK▾
Cash Flow & Enterprise
FCF?$-466000000
Enterprise Value?$2.4B
Fundamentals ratios updated end of day